Participants in the Grace Initiative

We would like to acknowledge and thank our contributors, testers, and supporters.

Formal Organizational Endorsement

International Society of Pharmacoepidemiology (April 2010)

Contributors, Collaborators and Supporters

Contributors have provided periodic consultation and advice
Marc L. Berger, Innovus
Sarah Garner, Research & Development, NICE
Tobias Gerhard, Ernest Mario School of Pharmacy, Rutgers University
Barbara McNeil, Health Care Policy, Harvard Medical School
Newell McElwee, US Outcomes Research, Merck & Co., Inc.
Peter Neumann, Director, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center; Professor, Tufts University School of Medicine
Steve Pearson, President, Institute for Clinical and Economic Review, Massachusetts General Hospital Institute for Technology Assessment
Sebastian Schneeweiss, Harvard Medical School; Dept. of Medicine, Brigham & Women's Hospital
Harold C. Sox, Professor of Medicine (emeritus, active), Dartmouth Medical School; Associate Director for Faculty; The Dartmouth Institute for Health Policy and Clinical Practice

Testers have assisted with checklist validation
Quazi Ataher, Worldwide Safety Strategy, Pfizer
Denise Boudreau, Pharmacoepidemiology, Group Health Research Institute
Suzanne Cadarette, Pharmacoepidemiology and Health Services Research, U. of Toronto
Tara Chang, Stanford School of Medicine
Moni Choudhury, Research & Development, NICE
Preciosa Coloma, Medical Informatics, Erasmus Medical Center
Nicole Cossrow, Worldwide Market Access, Johnson & Johnson
Concetta Crivera, Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC
CV Damaraju, Biostatistics, Janssen R&D
Cynthia de Luise, Worldwide Safety Strategy, Pfizer
Jenny Devenport, Biostatistics, Genentech
Eric Elkin, Late Phase & Outcomes Research (ILPOR), ICON
Sherif Eltonsy, University of Montreal
Joy Frestedt, Clinical Research, Frestedt Incorporated
Christiane Gasse, National Centre for Register-based Research, Aarhus University, Denmark
Yvonne Geissbühler, Global Epidemiology, Novartis Pharma AG
Cynthia Girman, Epidemiology, Merck Research Laboratories
Lisa Griffin-Vincent, Regulatory & Clinical Research Institute, Inc.
Joanna Haas, Global Patient Safety and Risk Management, Genzyme
Daniel Hartung, Pharmacoeconomics, Oregon State University
Jinghua He, Pharmacoepidemiology, Merck Research Laboratories
Kim Heithoff, US Outcomes Research, Merck & Co., Inc.
Ken Hornbuckle, Global Patient Safety, Eli Lilly and Company
Xing-Yue Huang, Health Economics and Outcomes Research, Forest Research Institute, Inc.
Mike Ingham, Health Economics & Outcomes Research, Janssen Biotech
Ralph Insinga, Health Economics and Statistics, Merck Research Laboratories
Henny Bang Jakobsen,Medical Sciences, Nycomed: a Takeda Company
Ani John, Immunology Registries, Genentech
Juhaeri Juhaeiri, Pharmacoepidemiology, Sanofi-Aventis
Marmar Kabir-Ahmadi, Epidemiology, Sanofi France
Bindweep Kaur, Research & Development, NICE
Wei Liu, Channing Laboratory, Harvard University
Laura Menditto, US Health Outcomes, GlaxoSmithKline
Donald R. Miller, Epidemiology and Health Services Research, Boston University
Debbie Moritz, Epidemiology, Genentech
Joaquin Mould, Health Econ. & Outcomes Res., Latin America & Primary Care Products, Pfizer
Erwan Muros, Global Medical Science & Communication, Actelion Pharmaceuticals Ltd.
Siva Narayanan, Medical Affairs, Human Genome Sciences, Inc.
Winnie Nelson, Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC
William Olson, Research and Analysis Strategy, Janssen Scientific Affairs, LLC
Niki Palmetto, Worldwide Safety Strategy, Pfizer
Mary Panaccio, US Medical Affairs, Sanofi-Aventis
Diane Randall, CNS Operations, Bristol-Myers Squibb
Valencia Remple, Health Economics & Outcomes Research, Pfizer
Karie Rosolowski, American Society of Plastic Surgeons
Matthew Rousculp, Comparative Effectiveness Research, GlaxoSmithKline
Tarang Sharma, Research & Development, NICE
Paul Stang, Epidemiology, Johnson & Johnson Pharmaceutical Research and Development
Iris Tam, Managed Care Medical Communications, Genentech
Boxiong Tang, Outcomes Research, Pfizer Inc.
Thang Tran, Health Economics & Outcomes Research, Pfizer
Sarah T. Tonn, Clinical Quality and Performance Evaluation, American Academy of Neurology
Patrice Verpillat, Global Market Access and Pricing Strategies, Sanofi-Aventis
Naunihal S. Virdi, Medical Affairs, LifeScan
Linda Yau, Biometrics & Health Outcomes and Payer Support, US Medical Affairs, Genentech
Marianne Yood, EpiSource
Yunming Mu, Biostatistics, Genentech
Jie Zhang, Health Economics and Outcomes Research, Novartis Pharmaceuticals Corp.
Helga Zoega, Mt. Sinai Medical Center

Other Collaborators and Supporters have provided constructive comments
José Luis Alloza, Dep. de Farmacología-Facultad de Medicina, The U. of Alcalá, Madrid, Spain
G. Lawrence Atkins, PhD, Public Policy and Reimbursement, Schering-Plough
Jesse Berlin, Pharmacoepidemiology, J&J Pharmaceutical R&D
Michael N. Cook, Global Safety Surveillance & Epidemiology, Pfizer
Christina Farup, Evidence Based Medicine, Novartis
Richard Gliklich, President, Outcome
R.M.C. Herings, PharmD, Dpt of Health Policy and Mgmt, Erasmus MC. Rotterdam, The Netherlands
Ken Hornbuckle, Risk Management & Pharmacoepidemiology, Eli Lilly
Mark V. Johnston, College of Health Sciences. University of Wisconsin
Kristijan Kahler, HE&OR, ABGU & NS Evidence Based Medicine, Novartis
Stephen Motsko, Risk Management & Pharmacoepidemiology, Eli Lilly
Dan Ollendorf, Institute for Clinical & Economic Review
John Parkinson, General Practitioners Research Database
Jeff Schein, Scientific Affairs, Ortho-McNeil Janssen
Hemal Shah, Health Economics & Outcomes Res., Boehringer Ingelheim Pharmaceuticals, Inc.
Daniel E. Singer, Clinical Epidemiology, Harvard Medical School; Epidemiology, Outcomes, and Disease, Management Unit, MGH Clinical Research Program
J. Michael Sprafka, Epidemiology and Pharmacoeconomics, Procter & Gamble
Til Stürmer, Dept. of Epidemiology, U. of North Carolina, School of Public Health, Chapel Hill
Sean Tunis, Center for Medical Technology Policy (CMTP)
Alexander M. Walker, Principal, Whiscon
Douglas J. Watson, Medical/Scientific Liaison, Merck Research Laboratories